PReS-FINAL-2160: Intestinal microbiome in polyarticular juvenile idiopathic arthritis: a pilot study

نویسندگان

  • PC Hissink Muller
  • PM Westedt
  • AE Budding
  • CF Allaart
  • DM Brinkman
  • TW Kuijpers
  • JM Van den Berg
  • LW Van Suijlekom-Smit
  • MA Van Rossum
  • TG De Meij
  • R Ten Cate
چکیده

Results Faeces of 8 (6 girls, 2 boys) children with polyarticular JIA, all rheumatoid factor negative were investigated and compared to 24 healthy controls. Anti-Nuclear Antibodies were positive in 3 patients. Median age at evaluation was 11.1 years (7.3-13.1), median period from start complaints to diagnosis was 7.1 months (4.4-13.2). Median ACR pedi scores were: VAS physician 47 mm(32-58), VAS patient well-being 32 mm(27-52), ESR 8 mm(2-9), active joint count 10(7-14), limited joint count 2 (0-4), CHAQ score 1.2 (0.4-1.7). One intra-articular steroid injection was given to each of two patients respectively 1 and 4 months prior to stool collection. Non Steroidal antiinflammatory Drugs (nsaids) were used by all patients at the time of evaluation. Median age of the healthy controls was 10.6 years (8.4-12.9). The median Simpsons’ diversity index within the phylum Firmicutes in controls and JIA was 0,88, and 0,83 respectively (p < 0,012). Diversity within the phyla Bacteriodetes and Proteobacteria did not differ between the 2 subgroups. By constructing a Pearson-correlation dendogram, no clustering was seen between the JIA group and the healthy controls on species-level (figure 2), a specific JIA associated microbiotal signature could not be identified.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH

PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticularcourse juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH F De Benedetti, N Ruperto, Z Zuber, R Cuttica, R Xavier, I Calvo, N Rubio, E Alekseeva, V Chasnyk, J Chavez, G Horneff, V Opoka-Winiarska, P Quartier, A Spindler, C Keane, K Bharucha, J Wang, D Lovell, A Martini, HI Brunner, PRINTO and PRCSG

متن کامل

PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients

Introduction TCZ, an IL-6R inhibitor, is effective in systemic and polyarticular juvenile idiopathic arthritis (sjia, pjia). BWadjusted, intravenous dosing regimens (TCZ8 mg/kg Q2W for sjia and Q4W for pjia) were assessed in Japanese phase 3 trials. As shown in Results, BW adjustment led to lower TCZ exposure with lower BW; thus, higher doses were proposed for patients (pts) with BW<30 kg in th...

متن کامل

PReS-FINAL-2064: Effect of Goloimumab a new anti-TNF, in patients with the diagnosis of juvenile idiopathic arthritis

Results 18 patients with the diagnosis of juvenile idiopathic arthritis (15 with juvenile enthesitis associated arthritis, 2 with juvenile psoriatic arthritis and 1 with juvenile idiopathic polyarticular arthritis), for a mean time of 13.7 months per patient (4-26 months). 16 patients have been treated with other biologic agents before. In 13 patients Golimumab was started because of disease pr...

متن کامل

PReS-FINAL-2327: Abatacept in the treatment of refractory uveitis

Introduction Uveitis is one of the most serious manifestations of Juvenile Idiopathic Arthritis (JIA), with the potential to cause severe sight-threatening ocular complications. The first line treatment consists of topical and oral steroids with DMARDs therapy for more severe cases, including immunosuppressive and anti-TNFa agents. Abatacept (CTLA-4 immunoglobulin) is a soluble, fully human fus...

متن کامل

PReS-FINAL-2070: Efficacy of biologic treatments in juvenile idiopathic arthritis with a polyarticular course: an indirect comparison

Methods Based on a literature review, we identified RCTs of abatacept, adalimumab (ADA), etanercept, infliximab and tocilizumab (TCZ) in pcJIA. Comparative effectiveness was estimated on the reported American College of Rheumatology response rates (JIA ACR30/50/70/90) measured at the end of the randomised, double-blind phase by means of a Bayesian indirect comparison using a fixed-effects order...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 11  شماره 

صفحات  -

تاریخ انتشار 2013